IL3RA (Interleukin 3 Receptor Subunit Alpha)

P1, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 --> Dec 2029

PVEK, with convenient dosing, led to high, durable responses, especially in frontline BPDCN, and a manageable safety profile.

The t(16;21)(p11;q22) FUS::ERG fusion gene is rare in pediatric AML and associated with poor prognosis. Allo-HSCT may mitigate the adverse prognostic impact of the FUS::ERG fusion gene and contribute to prolonged survival.

P1/2, N=31, Recruiting, Jacqueline Garcia, MD | Trial completion date: Dec 2028 --> Dec 2030 | Trial primary completion date: Dec 2026 --> Dec 2028

We demonstrate that DISCERN can track phenotypic plasticity in leukemia cells and identify stem-like subsets in leukemia xenograft models. This cost-effective and robust platform provides a promising tool for AML risk stratification, relapse prediction, and precision therapy.

Validation of the prognostic FCM-PS in an independent patient cohort confirmed good discrimination performance (AUC: 0.70). We introduce a unique, easy-to-use prognostic FCM-PS score (panel: CD45/CD34/CD117/CD33/CD19/CD123/HLA-DR) for OS in MDS, allowing refined risk stratification for IPSS-R subgroups.

P1/2, N=56, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=104 --> 56 | Trial completion date: Jan 2027 --> Mar 2026 | Trial primary completion date: Jan 2027 --> Oct 2025

P1, N=13, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Aug 2025 | Trial primary completion date: May 2026 --> Aug 2025

AML with KMT2A-PTD shows distinctive immunophenotypic features with increased CD123 and aberrant CD25 expression, both associated with FLT3-ITD. These markers may have diagnostic and therapeutic relevance in this AML subtype.

We propose the "Hamburger Sign" to describe characteristic imaging findings of the blastic plasmacytoid dendritic cell neoplasm, that is, the dermal T2-dark "patty" is sandwiched by tumor "buns" and the superficial and deep tumor components. Early recognition of this sign may prompt appropriate immunohistochemical work-up (plasmacytoid dendritic markers of TCF4, CD123, and TCL1) and expedite diagnosis, particularly when initial biopsy suggests undifferentiated carcinoma.

P1, N=32, Terminated, AvenCell Europe GmbH | N=90 --> 32 | Trial completion date: Sep 2025 --> Apr 2025 | Active, not recruiting --> Terminated; business decision by sponsor

Serial assessments were performed before and during treatment with bortezomib and dexamethasone for MM, and later with daunorubicin/cytarabine for AML. It demonstrates the earliest events in pDC-AML evolution. Furthermore, the immature immunophenotype raises the question of appropriate treatment, since a diagnosis of acute undifferentiated leukemia can be established.